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Abstract:  Post-translational modifications of chromatin contribute to the epigenetic 
control of gene transcription. The response to food intake and individual nutrients also 
includes epigenetic events. Bile acids are necessary for lipid digestion and absorption, and 
more recently have emerged as signaling molecules. Their synthesis is transcriptionally 
regulated also in relation to the fasted-to-fed cycle, and interestingly, the underlying 
mechanisms include chromatin remodeling at promoters of key genes involved in their 
metabolism. Several compounds present in nutrients affect gene transcription through 
epigenetic mechanisms and recent studies demonstrate that, beyond the well known anti-
cancer properties, they beneficially affect energy metabolism. 
Keywords:  fasted-to-fed cycle; gluconeogenesis; bile acid synthesis; cholesterol 
metabolism; chromatin; histone deacetylases; transcriptional regulation; resveratrol; 
sirtuins 
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1. Introduction 
The increasing understanding of relevant biological processes and the development of sensitive and 
high-throughput technical approaches to study important cellular functions have allowed us to 
investigate in depth the molecular mechanisms underlying the effects of nutrients and individual 
compounds in mammals. A number of dietary components exert their beneficial effects on human 
health by modulating the expression of genes involved in the pathogenesis and/or in the protective 
mechanisms relative to epidemiologically relevant diseases (e.g., cancer, cardiovascular diseases). In 
this respect, the downstream effects of post-translational modifications of histone proteins and other 
DNA-interacting proteins are emerging as crucial aspects contributing to the phenotypic response to 
food intake and to individual nutrients. 
The general purpose of this review is to summarize experimental observations documenting that 
chromatin remodeling in specific regions: (i) participates in the metabolic adaptation to the fed-fasting 
cycle, and (ii) is influenced by compounds either found in food or derived from metabolic 
transformation of food components. 
To this aim, basic concepts in epigenetics, chromatin dynamics, and the post-translational 
modifications through which chromatin is remodeled, will be reviewed. Particular emphasis will be 
given to histone deacetylases and sirtuins that have emerged as key factors in the remodeling of 
nucleosomes, and regulators of the association and activation state of transcriptional factors and 
cofactors to target promoters. Then, we will describe how epigenetic mechanisms contribute to the 
physiological response of the “eating-not eating” cycle, focusing in particular on gluconeogenesis and 
bile acid synthesis, two metabolic pathways that are modulated at the transcriptional level through 
similar regulatory mechanisms in response to hormonal stimuli. Furthermore, we will discuss how bile 
acids, terminal products of cholesterol synthesis and signaling molecules, by promoting the association 
of several chromatin remodeling proteins, modulate gene transcription. Finally we will present an 
overview of experimental studies reporting the molecular effects of dietary regimens or dietary 
supplementations that, in different ways, affect chromatin structure and gene transcription, thus 
possibly benefiting the treatment of metabolic disorders. 
2. Basic Concepts in Epigenetics 
Epigenetics can be defined as any inheritable influence on gene activity that does not involve a 
change in DNA sequence. In all eukaryotic cells, genomic DNA is folded and compacted by histone 
and non-histone proteins to form nucleosomes, and a further structured and dynamic form, generally 
referred to as chromatin. DNA packaging must be considered as a way to store and retrieve 
information since it represents a dynamic switch between transcriptional “on-off” states that result in 
gene activation and gene silencing. The term euchromatin refers to accessible and transcriptionally 
active genomic regions, while heterochromatin is composed of highly condensed and transcriptionally 
less active genetic material. 
In general, the epigenetic control is accomplished by means of two major mechanisms: methylation 
of cytosine residues in the DNA sequence and modifications of histones and other chromatin-
associated proteins. Referring to the latter mechanism, it has long been known that histone tail domains Nutrients 2010, 2                                       
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can be covalently modified by acetylation, phosphorylation, methylation and ADP-ribosylation at 
specific amino acid positions (Figure 1) in a way that regulates the contacts with the underlying   
DNA [1]. More recently, it has become evident that acetylation, phosphorylation, and newly 
discovered modifications (e.g., ubiquitination and sumoylation) also occur at the level of other 
chromatin associated proteins, transcription factors, transcriptional co-activators and co-repressors, 
thus modulating their function, and ultimately regulating gene transcription (Figure 1). 
Figure 1. The dynamics of DNA packaging. Post translational modifications of histone 
and non-histone proteins impose changes in the nucleosomal organization and represent the 
dynamic switch between transcriptional “on-off” states of chromatin. 
 
2.1. The Histone Code 
The term “histone code” was proposed in 2001 by Jenuwein and Allis [2] to define a marking 
system consisting of amino-terminal modifications of histone proteins. These modifications are then 
read by effector molecules, for example co-activators and co-repressors of gene transcription, and 
translated into biological functions, including transcription. It has been suggested that these chromatin 
marks might function in a combinatorial manner, thus increasing their indexing potential or capacity. 
Altogether, this marking system considerably extends the information potential of the genetic code, 
and represents an important level of regulation in response to endogenous and exogenous stimuli. 
2.2. Chromatin Remodeling Enzymes 
As mentioned above, histones and chromatin-associated proteins are the targets of multiple post-
translational modifications and several enzymes act on chromatin by introducing different post-
translational modifications at specific amino acids. These modifications include methylation of 
arginine residues; methylation, acetylation, ubiquitination, ADP-ribosylation, and sumoylation of 
lysines; and phosphorylation of serines and threonines [3]. 
A single histone protein presents several residues that can undergo post-translational modification 
giving rise to a variety of modified products. An example of this complexity is given by the peptide 
mass fingerprinting of core histones by mass spectrometric analysis that is able to detect methylation, 
acetylation, phosphorylation and ubiquitination. This analysis revealed the presence of 13 modification 
sites in histone H2A, 12 modification sites in histone H2B, 21 modification sites in histone H3, and 14 
modification sites in histone H4 [4]. Each site can either be unmodified or modified. In addition, some 
lysine residue can either be methylated or acetylated and there are three different possibilities for each Nutrients 2010, 2                                       
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methylated site (mono, di or tri). Therefore, histone proteins may undergo an extremely large number 
of possible combinations of modifications. 
The post-translational modification state of chromatin is the result of the balanced activity of 
several enzymes. For instance, the acetylation state of histones is the result of the activity of 
acetyltransferases and deacetylases. 
From the functional point of view, acetylation of histone H3 and H4 is associated with active 
transcription and commonly referred to as euchromatin modifications. This is most likely due to the 
fact that acetylation loosens inter- or intra-nucleosomal DNA-histone interactions and, at the same 
time, affects recognition and protein-protein interactions. On the other side, evidence
 suggests that 
methylation at lysine 9 of histone H3 is a mark for
  transcriptionally silent chromatin [5]. This 
modification can be catalyzed by specific enzymes, such as histone methyl transferase G9a, which is
 
localized exclusively in euchromatic regions [6]. 
2.3. Histone Deacetylases 
Addition of acetyl groups is one of the most widespread modifications of histones. Acetylation at  
-amino groups of lysine residues in histone tails neutralizes their positive charges, thereby relaxing 
chromatin structure. Furthermore, acetylated histones also serve as binding sites for bromodomain 
proteins, often acting as transcriptional co-activators. Histone acetylation occurs at multiple lysine 
residues; it is usually carried out by a variety of histone acetyltransferase complexes (HATs) and is 
reversed through the action of histone deacetylases (HDACs) [2,7]. 
HDACs do not bind DNA directly; in contrast, through the interaction with transcriptional 
activators and co-activators, they are recruited to target genes and are assembled in large multiprotein 
transcriptional complexes. Thus, the specific contribution of HDACs to the regulation of gene 
transcription depends on the cell type and on the availability of interacting proteins. 
HDACs represent a large super family of proteins whose members are grouped in different classes 
(Table 1) [8]. Class I HDACs are ubiquitously expressed and found predominantly in the nuclear 
compartment. They bear a conserved deacetylase domain and are active on histone substrates. The 
catalytic domain consists of a narrow, tube-like pocket, at the bottom of which a zinc cation is 
positioned. In cooperation with two histidine-aspartate charge relay systems, the zinc cation facilitates 
the deacetylation reaction. 
Class IIa HDACs carry a large N-terminal with conserved binding sites for the transcription factor 
myocyte enhancer factor 2 (MEF2) and the chaperone protein 14-3-3. Upon phosphorylation by means 
of different kinases, class IIa HDACs bind 14-3-3 and translocate from the cytoplasm to the   
nucleus [9-12]. Class IIa HDACs possess only minimal histone deacetylase activity, a behavior that 
can be explained with the fact that a key tyrosine residue in the catalytic domain is substituted with a 
histidine in class IIa HDACs [13]. A critical point in the evaluation of histone deacetylase activity is 
the physical interaction between class I and class II HDACs. In fact, it was shown that HDAC4 (class 
IIa) recruits pre-existing enzymatically active complexes containing HDAC3 (class I) and nuclear co-
repressors (NCo-R and SMRT), and that these protein-protein interactions are crucial in the 
transcriptional repression mechanisms involving histone deacetylation [14]. These evidences suggest Nutrients 2010, 2                                       
 
 
555
that class II HDACs behave as bridging molecules with little enzymatic activity, however at present it 
cannot be excluded that these enzymes act on other substrates that are still unknown. 
The most characterized member of class IIb HDACs is HDAC6, a cytoplasmic protein that acts on 
non-histone substrates such as cytoskeletal proteins and transmembrane proteins [8]. 
Finally, HDAC11 is the only member of class IV whose functions are still elusive [8]. 
2.4. Beyond Histones  
As briefly mentioned above, histones are not the only proteins whose biological activities are 
modulated by the acetylation state at lysine residues [15]. In particular, acetyltransferases themselves, 
such as the transcriptional coactivators p300 and CREB (cyclic AMP response element-binding 
protein) binding protein (CBP), are heavily acetylated. Acetylation at lysine residues occurs also at the 
level of other transcription factors and cofactors. In addition, also cytoplasmic proteins present 
acetylation sites.  
Sirtuins were initially discovered as silencing factors and longevity-linked proteins in lower 
organisms. The discovery that they act as NAD
+-dependent histone deacetylases [16] represented a 
significant breakthrough that allowed appreciating the multiple roles played by these enzymes in 
patho-physiology. Besides on histones, sirtuins act on a variety of acetylated substrates with different 
functions. SIRT1 deacetylates transcription factors and co-activators such as p53, nuclear factor κB, 
proteins belonging to the forkhead box type O (FOXO) family, the nuclear receptors peroxisome 
proliferator activated receptor (PPAR) γ, farnesoid X receptor (FXR), PPAR γ-coactivator 1 (PGC-1) ; 
but it also acts on enzymes such as acetyl-CoA synthetases, or on structural proteins such as -tubulin 
and heat shock proteins [17,18]. 
Table 1. The mammalian histone deacetylase superfamily. The list does not include class 
III HDACs, a term sometimes used to indicate sirtuins, a distinct group of deacetylases. 
Class Protein  domains  Members 
Class I  Deacetylase catalytic domain 
Phosphorylation sites (serine residues) at C terminus 
 
HDAC1 
HDAC2 
HDAC3 
HDAC8 
Class IIa  Deacetylase catalytic domain 
Phosphorylation sites (serine residues) at N terminus 
Myocyte enhancer factor binding sites 
Binding sites for 14-3-3 chaperone protein 
HDAC4 
HDAC5 
HDAC7 
HDAC9 
Class IIb  Deacetylase catalytic domain 
Zinc finger domain or leucine rich region 
HDAC6 
HDAC10 
Class IV  Deacetylase catalytic domain  HDAC11 
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3. Epigenetic Regulation of Metabolic Pathways 
In recent years, chromatin remodeling events have been demonstrated to be widely involved in the 
transcriptional control of metabolic homeostasis. In parallel with the advances in the understanding of 
the role of chromatin dynamics in patho-physiology, the ability of specific foods and of dietary 
regimens to exert beneficial effects through epigenetic mechanisms has been taken into consideration 
and investigated in more depth. The hypothesis is that either the response to food intake and to 
individual compounds present in or deriving from foods may affect chromatin structure. 
Actually, a large number of studies have clearly demonstrated that some dietary components affect 
gene transcription, through multiple mechanisms. To mention few examples, fatty acids can act as 
ligands of membrane and nuclear receptors, thus regulating intracellular signaling and gene   
expression [19,20], while polyphenols, present in a large number of food sources, exhibit anti-
inflammatory activities by interfering at multiple levels with the activation cascade of nuclear factor-
κB, a key regulator of the inflammatory response [21]. 
Deciphering the impact of dietary regimens (e.g., fast-feeding cycle, calorie restriction) or of 
specific nutrients (e.g., vegetables, fibers) on epigenetics will provide essential information for the 
“evidence-based” assessment of their benefits on human health. 
3.1. The Fed-Fasting Cycle: the Role of Bile Acids 
Bile acids possess multiple functions. Due to their amphipathic nature, through the formation of 
mixed micelles, they promote solubilization and transport of lipids in an aqueous environment, thus 
actively contributing to intestinal digestion and absorption of lipids. Primary bile acids are produced in 
the liver from cholesterol through a complex and highly regulated pathway [22]. The first reaction in 
this pathway, the hydroxylation of cholesterol at the 7α position, is catalyzed by the enzyme 
cholesterol 7α-hydroxylase (CYP7A1) and represents the rate-limiting step of the whole pathway. 
A major breakthrough in our understanding of bile acid biology came in recent years with the 
discovery that bile acids are the physiological ligands of a nuclear receptor, the farnesoid X receptor 
(FXR), and that bile acid-dependent activation of FXR underlies the feedback regulation exerted by 
bile acids on their own synthesis [23,24]. According to the proposed model, bile acid-activated FXR 
binds a responsive element in the promoter of small heterodimer partner (SHP) that acts as a 
transcriptional repressor at the promoters of target genes, such as CYP7A1 (Figure 2). Nutrients 2010, 2                                       
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Figure 2. Model describing the molecular basis for feedback regulation of bile acid 
synthesis. The scheme is based on the findings reported by Goodwin et al. and Lu et al. 
[23,24]. It is worth noting that the functions of liver receptor homolog 1 (LRH-1) were 
revisited more recently and it was concluded that, although this orphan nuclear receptor 
contributes to bile acid homeostasis, its role in the regulation of CYP7A1 gene is 
unexpectedly negligible, at least in the mouse [25]. 
 
 
Although the FXR pathway is responsible for most of the biological effects exerted by bile acids on 
gene transcription, the analysis of shp-deficient mice indicated that bile acids down-regulate their 
synthesis, and particularly the CYP7A1 gene, also by means of additional mechanisms [26,27]. In this 
regard, we showed that bile acids repress the transactivation potential of hepatocyte nuclear factor 
(HNF)-4α, a potent activator of CYP7A1 transcription, in an FXR/SHP-independent manner [28,29]. 
Furthermore, we found that bile acids interfere with the recruitment of co-activator proteins, such as 
PGC-1α and CBP, to the CYP7A1  promoter in the native context of chromatin (Figure 2) [29]. 
Investigating whether a similar regulatory mechanism involving chromatin remodeling could apply to 
other genes transactivated by HNF-4α, we found that bile acids repress the expression of the gene 
encoding the phosphoenolpyruvate carboxy kinase (PEPCK), one of the key enzymes in 
gluconeogenesis, through a mechanism highly similar to that described for CYP7A1 [29] (Figure 3).  Nutrients 2010, 2                                       
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Figure 3. Model describing the mechanism by which bile acids disrupt the formation of a 
transcriptionally active complex at the promoters of CYP7A1 and PEPCK, the key genes in 
bile acid synthesis and gluconeogenesis, respectively. Hepatocyte nuclear factor (HNF)-4 
bound to a sequence named BARE (bile acid responsive element) interacts with the co-
activators PGC-1α and CBP. These protein-protein interactions may promote DNA 
bending and formation of a multiprotein complex containing general transcription factors 
(GTFs) and RNA polymerase (RNA pol) II. Bile acids interfere with the interactions 
between HNF-4 and co-activators and with the association of RNA pol II at the 
CYP7A1/PEPCK promoters causing reduction of gene transcription. 
 
 
A large fraction (~90%) of bile acids is reabsorbed by the intestinal mucosa and returns to the liver 
through the entero-hepatic circulation. Therefore, in the post-prandial phase, a high amount of bile 
acids reaches the liver through the portal vein. In contrast, in the fasting condition, the circulating 
levels of bile acids drop significantly. A well known hallmark of the fasted state is the raise in 
glucagon plasma level that triggers a signaling cascade in target tissues, particularly the liver, 
associated with increased intracellular levels of cyclic-AMP (cAMP) that are responsible for the 
metabolic adaptation to fasting. The PEPCK gene is one of the most regulated genes in the fasted-to-
fed cycle, being highly expressed in fasting when the gluconeogenesis rate is high, and dramatically 
repressed in the postprandial condition. Based on cellular studies demonstrating that both CYP7A1 and 
PEPCK are regulated in a similar fashion by opposing stimuli such as bile acids and cAMP, the first 
mimicking postprandial conditions and the latter the fasted state [29], we investigated whether this 
regulation may also be working in vivo. In fact, we found that fasted mice express higher levels of Nutrients 2010, 2                                       
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CYP7A1 and PEPCK in comparison to fed animals [29]. Based on these evidences, we propose that the 
fasted-to-fed cycle regulates apparently unrelated metabolic pathways (bile acid synthesis and 
gluconeogenesis) in a coordinated fashion. 
After a prolonged fasting period, the transcription of CYP7A1 and PEPCK increases; probably in 
response to the stimulation by the glucagon/cAMP cascade and to the concomitant decrease in the 
concentration of bile acids returning to the liver. On one hand, this may help to prepare the 
gastrointestinal tract for the digestion and absorption of fats in a subsequent meal and, on the other 
hand, to increase hepatic glucose production in order to buffer the falling plasma concentration of 
glucose during the fasted state. Conversely, in the fed state, as the concentration of bile acids fluxing 
through the entero-hepatic circulation increases, the reduction of CYP7A1 and PEPCK transcription 
may be secondary to the drop in the glucagon level and to the direct inhibition elicited by bile acids, 
which are massively secreted into the duodenum and return to the liver at higher concentrations than 
during a prolonged fasting period (Figure 4). 
3.2. Sirtuins: Key Players in the Fed-Fasting Cycle and Calorie Restriction 
In mammals, sirtuins regulate a variety of functions, from the control of cellular stress to energy 
metabolism [30]. The first indication that sirtuins, in particular SIRT1, are involved in the metabolic 
control in mammals came from the elegant studies of P. Puigserver and coworkers, who were 
investigating the molecular mechanisms responsible for the adaptive metabolic response to fasting. 
Reduced availability of nutrients, such as that experienced in fasting and calorie restriction, is reflected 
at the cellular level by a decrease of oxidative pathways and, consequently, by an increase of 
NAD
+/NADH ratio. Rodgers et al. found that in the fasted state, SIRT1 is induced in the liver and 
deacetylates PGC-1α at specific lysine residues in an NAD
+-dependent manner [31]. Deacetylated 
PGC-1α more actively transactivates the transcription of target genes, particularly those involved in 
gluconeogenesis [31]. In line with these observations, the knock-down of SIRT1 in the liver leads to 
reduced glucose production and fatty acid oxidation in the liver, under fasting conditions [32]. These 
metabolic changes are linked to decreased expression of genes responsible for gluconeogenesis and 
fatty acid oxidation [32]. These studies clearly demonstrate that SIRT1 is a key regulator of metabolic 
adaptation to nutrient deprivation and that PGC-1 mediates most of SIRT1 effects. Mitochondria play 
a central role in metabolic homeostasis and can be considered preferential targets of both SIRT1 and 
PGC-1. In fact, the mitochondrial respiratory chain is the main contributor to the NAD
+/NADH 
equilibrium, oxidative pathways, i.e., the Krebs cycle and -oxidation of fatty acids, are localized in 
mitochondria, and finally, PGC-1 promotes the transcription of mitochondrial genes and 
mitochondrial biogenesis [33]. 
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Figure 4. Metabolic changes occurring in the fasted-to-fed cycle. In the fasted state, 
plasma levels of glucagon are high while the levels of bile acids are low. These signals 
contribute to the regulation of gene transcription, and the downstream effects are up-
regulation of gluconeogenesis and bile acid synthesis. In the fed state, there is a rise of 
insulin plasma levels and an increase of bile acids returning to the liver from the intestine. 
Both signals affect gene transcription and, in particular, bile acids repress both CYP7A1 
and PEPCK, thus contributing to the repression of gluconeogenesis and bile acid synthesis.  
 
3.3. Bile Acid-Induced Post-Translational Modifications of Histones and Chromatin Remodeling 
The atypical orphan nuclear receptor SHP, as mentioned above, is a crucial player in the signaling 
pathway by which bile acids regulate several aspects of cholesterol and bile acid metabolism and 
transport. The simple model proposed initially (Figure 2), according to which bile acid-activated FXR 
promotes the transcription of SHP, represented a starting point for subsequent investigations that 
allowed disclosing the contribution of chromatin dynamics to bile acid-sensitive regulatory cascades. 
The analysis of the CYP7A1 promoter showed that bile acids do not cause dramatic structural 
changes such as nucleosome sliding or disruption [34,35]. However, bile acid treatment results in 
decreased accessibility of DNA in nucleosome cores to endonucleases in euchromatin, including the 
CYP7A1 promoter [34,35,36], indicating a remodeling of the chromatin. Based on the knowledge that 
chromatin can undergo remodeling driven by ATP hydrolysis, Kemper et al. demonstrated that the bile 
acid-induced SHP is recruited to the CYP7A1 promoter in association with the repressive complex 
Swi/Snf that contains the ATPase Brm [35,37]. In addition, SHP promotes the association of a co-
repressor complex containing two other chromatin modifying enzymes, HDAC1 and HDAC2 [35,36]. 
Indeed, the interaction of SHP with histone proteins, in particular with histone H3, is highly influenced 
by post-translational modifications. In fact, SHP associates with non acetylated/methylated histone H3 Nutrients 2010, 2                                       
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and acetylation of histone H3 at lysine 9 prevents this interaction [36]. SHP also induces the 
recruitment of the G9a methyltransferase [34,36] and the resulting modifications at lysine 9 of histone 
H3, that is, methylation by G9a and deacetylation
 by HDACs are interdependent and necessary for the 
recruitment
 of the Swi/Snf-Brm complex, which is essential for SHP-mediated
 transcriptional silencing 
of the CYP7A1 gene [34]. 
As mentioned above, bile acids are able to trigger SHP-independent mechanisms that contribute to 
the feedback regulation of CYP7A1, especially in the initial phase when bile acid-induced SHP protein 
has not been synthesized yet. Therefore, we investigated the changes imposed by bile acids to 
chromatin structure in this lag of time, analyzing the composition of the transcriptional complex at the 
CYP7A1 promoter [38]. While the co-activators PGC-1α and CBP dissociate from the promoter in bile 
acid treated liver cells, several co-repressor factors are recruited. In parallel we observed dissociation 
of RNA polymerase II either from the promoter or from the 3’untranslated region of the CYP7A1 
gene. Interestingly, we also found a reduced phosphorylation of RNA polymerase II at the serine-2 
residue, which results in a less transcriptionally active enzyme. The structural changes of chromatin 
also involve the acetylation state; in fact we found that bile acids induce hypoacetylation of histone 4, 
most likely as a result of a sequential recruitment of several histone deacetylases, HDAC3 and HDAC7 
in a first phase, and then HDAC1. In line with these observations, the treatment with HDAC inhibitors 
prevented the inhibitory effect of bile acids on the mRNA levels of CYP7A1 of liver cells, and 
derepressed the expression of the enzyme in mice. To assess the contribution of specific HDACs in 
this regulatory mechanism, we knocked down the HDAC isoforms recruited in the repressive complex 
at the CYP7A1 promoter by RNA interference and we found that only the silencing of HDAC7 
prevents the inhibition of CYP7A1 expression by bile acids. Notably, HDAC7 belongs to class II, and 
its sub-cellular localization depends on its phosphorylation state, since it is sequestered in the 
cytoplasm when phosphorylated. We observed that bile acids promote the nuclear translocation of 
HDAC7 and that calyculin, a phosphatase inhibitor, prevents the effects of bile acids on HDAC7 
translocation and the feedback on CYP7A1 transcription. 
The chromatin remodeling events occurring in the feedback regulation of CYP7A1 are summarized 
in Figure 5. 
As mentioned above, FXR is one of the initial targets of bile acid signaling and besides up-
regulating SHP, it positively modulates the expression of a number of genes involved in bile acid 
metabolism and transport.  
Consistent with the general function of nuclear hormone receptors, FXR participates in post-
translation modifications of chromatin, therefore the recruitment of co-activators that display 
acetyltransferase activity by activated FXR is not a novel finding. 
Other post-translational modifications, such as methylation of histones H3 and H4 following 
nuclear receptor activation, have emerged more recently. In relation to FXR, it was shown that this 
nuclear receptor, once activated by bile acids, associates with co-activator-associated arginine 
methyltransferase 1 (CARM1) at the gene locus of bile salt export pump (BSEP), a well-established 
FXR-target gene [39]. Enrichment of CARM1 leads to an increase of methylation at lysine 17 and of 
acetylation at lysine 9 of histone H3 in correspondence of the FXR binding element of BSEP gene, 
although the interdependence between histone H3 acetylation and methylation was not   
clearly established. Nutrients 2010, 2                                       
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Figure 5. The scheme depicts the role of chromatin remodeling enzymes in the 
transcriptional regulation of CYP7A1. In untreated hepatocytes, a transcriptionally active 
complex is assembled at the bile acid responsive element (BARE) (A). In addition to the 
factors reported in Figure 4, other proteins contribute to the transactivation, including liver 
receptor homolog (LRH)-1 and steroid receptor coactivator (SRC)-1. RNA pol II is 
phosphorylated and becomes more transcriptionally active. HDAC7 is sequestered in the 
cytoplasm. In these conditions, the arginine residues of histones, in particular histone H3, 
are acetylated (B). In the presence of bile acids, in a first phase, HDAC7 translocates to the 
nucleus and associates with the CYP7A1 promoter (A). The recruitment of other factors, 
HDAC3 and the silencing mediator for retinoid and thyroid-hormone receptors (SMRT), 
contributes to the formation of a repressive complex. By inhibiting phosphatases with 
calyculin, the bile acid-induced translocation of HDAC7 is blocked and the bile acid-
induced inhibition of CYP7A1 is prevented. On the other hand, bile acids induce the 
synthesis of SHP that acts as a repressor as depicted in Figure 2. In addition, SHP interacts 
with HDACs and G9a methyltransferase, which deacetylate and methylate, respectively, 
arginine residues of histone proteins (B). SHP also promotes the recruitment of the 
Swi/Snf-Brm complex that drives ATP-dependent chromatin remodeling, which further 
represses CYP7A1 transcription (B).  
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Furthermore, ligand-dependent activation of FXR was reported to promote the recruitment of 
protein arginine methyltransferase 1 (PRMT1) and histone H4 methylation to the promoter of BSEP 
and SHP genes [40]. 
4. Targeting Chromatin and Chromatin-Associated Factors: New Opportunities for Handling 
Metabolic Disorders  
A variety of epigenetic changes occur during cancer development [41], and particularly, disruption 
of HAT or HDAC activity can be associated with the development of cancer [42]. Therefore, the 
possibility to target tumor cells through epigenetic approaches, in particular by modulating HDAC 
activity, has emerged as a promising pharmacological tool for cancer therapy and several HDAC 
inhibitors have entered clinical trials in the last few years [43]. 
In addition to anticancer therapy, the detailed analysis of the epigenetic mechanisms responsible for 
the regulation of cholesterol catabolism described in the previous sections, provides the molecular 
rationale to envisage that HDACs, in particular HDAC7, could be targeted also to modulate   
cholesterol homeostasis. 
Furthermore, HDACs could also be targeted for the treatment of metabolic disorders such as insulin 
resistance and diabetes, on the basis of several evidences. First of all, genome wide scans for both  
type 1 and type 2 loci suggested that HDACs may be implicated in the pathogenesis of diabetes [44]. 
Furthermore, several studies demonstrated that HDACs, especially HDAC4 and 5, play a pivotal role 
in regulating the expression of metabolic genes in skeletal muscle [45-47]. 
Finally, emerging evidences indicate that SIRT1, owing to its deacetylating activity on a wide range 
of substrate proteins and to other deacetylase-independent effects, would represent a potential target in 
several diseases, from cancer to metabolic disorders. 
4.1. Histone Deacetylase Inhibitors 
In recent years several natural compounds have been added to the long list of HDAC inhibitors that 
comprises chemicals belonging to different classes, several of which have been approved by 
Government Agencies for the treatment of malignancies. 
The beneficial effects of dietary isothiocyanates and allyl sulfides on human health, and in 
particular their cancer chemopreventive effects, have been known for a long time [48,49], however, 
only recently their positive actions have been linked with epigenetic mechanism. A major 
understanding of HDAC active site structure and of the molecular features required to inhibit HDAC 
catalytic activity, in particular the presence of a spacer “arm” that allows the entry into the catalytic 
pocket and of a functional group interacting with the zinc cation, led to the reconsideration of the 
biological activity of several natural compounds.  
Sulforaphane (SFN) is one of the most characterized isothiocyanates found in vegetables. It derives 
from the glucosinolate glucoraphanin present in cruciferous vegetables, such as broccoli and broccoli 
sprouts. Like other isothiocyanates, it is metabolized via the mercapturic acid pathway to active 
metabolites, among which SFN-cysteine displays a good fit for HDAC active site according to 
computer modeling predictions [50]. Indeed, the effects of SFN in in vitro and in vivo systems are 
associated with increased global histone acetylation [51-53]. Nutrients 2010, 2                                       
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Allyl compounds are garlic components comprising diallyl disulfide and S-allyl mercaptocysteine, 
which are both converted into the active metabolite allyl mercaptane. Docking simulation revealed a 
good fit between allyl mercaptane and HDAC active site, consistent with accumulation of acetylated 
histones and growth arrest in cancer cells treated with the active metabolite at micromolar 
concentrations [54]. 
Finally, sodium butyrate should also be included in the list of naturally occurring HDAC inhibitors 
since it is generated during the fermentation of dietary fibers in the large intestine [55]. 
4.2. Effects of Histone Deacetylase Inhibitors on Cholesterol Metabolism 
Based on our findings reported above, we hypothesized that targeting HDACs with an appropriate 
inhibitor may release Cyp7a1  from the physiological repression caused by bile acids and, 
consequently, in vivo may also decrease blood cholesterol as a result of its enhanced conversion to bile 
acids. First of all, we could demonstrate that treatment of cultured liver cells with two chemically 
unrelated HDAC inhibitors, valproic acid and trichostatin A, indeed causes derepression of   
CYP7A1 [38]. Next, we tested the effects of HDAC inhibitors on cholesterol metabolism in Ldl-r
-/- 
mice, an animal model of genetic hypercholesterolemia caused by a defect of the low-density 
lipoprotein receptor. We found that both inhibitors dramatically elevate Cyp7a1 mRNA levels in   
Ldl-r
-/- mice [38]. Consistent with this, also fecal bile acid excretion, an index of bile acid synthesis, 
increases significantly in treated mice. But most interestingly, we also observed a parallel decrease of 
plasma cholesterol. The analysis of the expression profile of other key genes involved in cholesterol 
homeostasis showed no changes due to the treatment, thus confirming that the effects of HDAC 
inhibitors on plasma cholesterol levels in hypercholesterolemic mice are most likely secondary to their 
action on Cyp7a1. 
4.3. Effects of Histone Deacetylase Inhibitors on Energy Metabolism 
In addition to the effects on cholesterol and bile acid metabolism mentioned above, we also found 
that HDAC inhibitors affect in some way energy metabolism. In fact, we found that treated mice 
display decreased plasma triglycerides and no weight gain, despite increased food consumption (Mitro, 
Galmozzi, Gilardi, Godio, Scotti, Caruso, De Fabiani, Crestani, unpublished observations). A recent 
study provided further evidence supporting the involvement of HDACs in energy expenditure. In fact, 
Gao et al. reported that sodium butyrate, a dietary component found in cheese and butter and also 
produced in the large intestine after fermentation of dietary fibers, improves metabolic dysfunction in 
mice fed a high-fat diet [56]. In particular, supplementation with sodium butyrate prevents diet-
induced obesity, increase energy expenditure, and improves insulin sensitivity. These metabolic 
changes reflect beneficial effects of sodium butyrate on brown adipose tissue and skeletal muscle since 
treated mice show increased adaptive thermogenesis, and a higher number of oxidative fibers, coupled 
with enhanced fatty acid oxidation and mitochondrial function, in skeletal muscles. 
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4.4. Effects of SIRT Activators on Energy Metabolism 
A detailed discussion on the multiple downstream effects following the modulation of SIRT1 
activity is far beyond the scope of this review. Therefore, here we will simply review the involvement 
of SIRT1 activation in the control of energy metabolism. 
In 2003, Howitz et al. reported for the first time that small molecules, such as the natural 
polyphenol resveratrol, can extend the lifespan of Saccharomyces cerevisiae in a Sir2-dependent 
manner [57]. Subsequent studies in animal models of insulin resistance and high-calorie diet showed 
that resveratrol administration ameliorates the metabolic derangements observed in these mice [58,59]. 
In particular, resveratrol attenuates adipogenesis and fat storage in white adipose tissue and, at the 
same time, improves mitochondrial activity and thermogenesis of brown adipose tissue. Resveratrol 
also affects insulin and glucose homeostasis since it increases insulin secretion from the pancreas and 
improves insulin sensitivity in the skeletal muscle, accompanied by enhanced mitochondrial activity 
and fatty acid oxidation. These metabolic effects are associated to activation of AMP-activated kinase 
and PGC-1. In particular, this latter effect is due to SIRT1-dependent deacetylation [58]. Indeed, all 
these factors are strictly and coordinately linked. In fact, AMP-kinase, a sensor of the cellular energy 
status that is activated by a rise of AMP/ATP ratio, enhances SIRT1 activity due to increased NAD
+ 
cellular levels and consequently causing deacetylation of PGC-1 and FOXO transcription   
factors [60]. 
Although the animal studies discussed above clearly indicated that the effects of resveratrol are 
SIRT1-dependent, the observation that this polyphenol also activates AMP-kinase, makes difficult to 
establish which the primary target of resveratrol is. In fact, resveratrol increases SIRT1 deacetylating 
activity toward synthetic substrates containing a fluorescent moiety, but appears to have no direct 
effect on physiological substrates [61,62]. 
Collectively, these evidences indicate that resveratrol can modulate gene transcription and, 
consequently, metabolic pathways through specific molecular mechanisms that are independent from 
its antioxidant properties.  
5. Final Considerations 
The fasted-to-fed cycle is characterized by hormonal fluctuations and by variations in the 
circulating levels of other signaling molecules that, through the entero-hepatic circulation, connect the 
gut to the liver. Recent studies have allowed reconsidering the function of bile acids in this respect, and 
have demonstrated that they participate in the regulatory mechanisms responsible for the metabolic 
adaptation occurring during the fasted-to-fed cycle, modulating the transcription of genes that play a 
key role in the synthesis of bile acids and gluconeogenesis. 
The metabolic adaptation to fasting and to calorie restriction is indeed very complex, and the 
intracellular decrease of energy substrates represents per se a signal that activates a program of 
metabolic adaptation involving SIRT1, AMP-kinase, and PGC-1. 
Emerging evidences indicate that nutritional-linked cues, such as bile acids themselves, regulate the 
transcription of these genes by affecting the structure of chromatin. Histone deacetylases are deeply Nutrients 2010, 2                                       
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involved in chromatin dynamics and inhibition of their activity represents a way to regulate cholesterol 
homeostasis and energy metabolism. 
Some nutritional compounds display the ability to affect the activity of chromatin modifying 
enzymes, i.e., by inhibiting HDACs or activating sirtuins, thus participating in the epigenetic control of 
metabolic pathways. Therefore dietary manipulation aimed at increasing the intake of these molecules 
may be beneficial in the management of metabolic disorders such as obesity, metabolic syndrome,  
and diabetes. 
When dealing with the biological effects of nutrients or of specific compounds present in foods, the 
nutritional aspects should be carefully considered. 
A first issue that may concern nutritionists is to establish whether the regular intake of certain foods 
(vegetables, fibers) is sufficient to provide the amount of specific compounds necessary to elicit the 
biological effects reported in experimental studies. Indeed, the animal studies documenting the 
beneficial effects of naturally occurring isothiocyanates or resveratrol were performed administering 
diets supplemented with high amounts (from few to several hundred mg/kg of body weight) of pure 
compounds. It is questionable that such high amounts of individual compounds can be reached in 
humans simply by eating foods enriched in these molecules. Furthermore, concentration, composition 
and stability of these compounds in foods may vary due to multiple reasons, e.g. cultivars, ripening 
period, preservation conditions, cooking. For example, three-day-old broccoli and cauliflower sprouts 
contain 10-100 times higher levels of glucoraphanin than the corresponding mature plants. 
One way to overcome this problem would be to prepare special foods or nutritional supplements 
enriched in these compounds. Resveratrol is present at high concentrations in the skins of red grapes 
and in the Japanese knotweed, a non-edible plant native to Eastern Asia that has become invasive in 
Western countries. Indeed, resveratrol tablets, prepared from plant sources, are advertised and 
marketed as nutritional supplement or “phytonutrient”. However, regarding its use as SIRT activator 
and therefore in the management of metabolic disorders, more studies are needed to establish whether 
beneficial effects ascribable to resveratrol can be obtained through the consumption of red grapes, red 
grape foods or directly by supplementing the diet with polyphenolic extracts [63]. 
In most cases natural compounds exhibit several biological activities contributing to the final effects 
in a whole biological system. Limiting the analysis to compounds acting through epigenetic 
mechanisms, we mention the example of isoflavones, abundant in plants of the Leguminosae family. 
These compounds were recently reported to induce mitochondrial biogenesis in cellular models, 
through SIRT and PGC-1, in an estrogen-independent manner [64]. However, isoflavones have been 
known for many years for their phytoestrogenic activities, therefore it is expected that the in vivo 
effects following the consumption of isoflavone-rich foods, will be the result of their multiple actions. 
  In conclusion, we expect that a deeper understanding of the epigenetic mechanisms involved in the 
control of metabolic pathways will allow to disclose novel effects associated either with dietary 
regimens (e.g., calorie restriction) or with consumption of specific nutrients (e.g., vegetables, fibers). 
Experimental studies, coupled with a thorough evaluation of nutritional aspects, are essential to assess 
the benefits of nutrition on human health through an “evidence-based” approach. 
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